Ocugen, Inc. Common Stock
OCGNStock
$1.37+33.64%52W
Market Cap$460.39M
P/E—
Div yield—
Beta2.16
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.52%
Price vs S&P 500 (4W)20.59%
VGM Score35.39
Market Capitalization$460.39M
Earnings Surprise History
Q1 26-0.06est. -0.05
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.15
4.15
4.15
4.15
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCGNOcugen, Inc. Common Stock | F | C | C | $1.37 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Ocugen Inc develops gene therapies, cell therapies, and vaccines targeting unmet medical needs across multiple therapeutic areas. The company's primary focus is on retinal diseases, including inherited conditions such as retinitis pigmentosa and Leber congenital amaurosis, as well as age-related diseases including dry age-related macular degeneration and geographic atrophy. Its pipeline includes modifier gene therapy, novel biologics, regenerative medicine cell therapies, and inhaled mucosal vaccine platforms.